Denali Therapeutics Inc. — AVLAYAH (Tividenofusp alfa) - (COMPASS) · Hunter syndrome MPS II.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (10/8/25) through T+5. Run-up high $22.74 on 2/3/26, low $14.41 on 11/13/25 (T-120 to T-1). FDA decision 3/25/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-03-25
OutcomeApproved
Drug / candidateAVLAYAH (Tividenofusp alfa) - (COMPASS)